Danilak Melanie, Chambers Carole R
Pharmacy Department, Cross Cancer Institute, Edmonton, Alberta, Canada.
J Oncol Pharm Pract. 2013 Jun;19(2):105-10. doi: 10.1177/1078155212455939. Epub 2012 Aug 15.
To determine how many breast cancer patients who initiated adjuvant endocrine therapy discontinued early and to evaluate adherence in patients who persisted with therapy. Secondary objectives were to explore possible trends to see if certain factors may correlate to early discontinuation of therapy.
A retrospective review of charts and pharmacy dispensing records was conducted, including patients who initiated adjuvant endocrine therapy for breast cancer at the Cross Cancer Institute from 1 January to 31 December, 2006.
Out of 346 patients, 81 (22%) discontinued therapy within 2 years. Adherence rates calculated for the 265 patients who remained on therapy beyond 2 years showed that 247 (93%) of these patients had 80% or better adherence. Patients who did not undergo chemotherapy and patients with Cross Cancer Institute follow-up times of less than 1 year were significantly more likely to discontinue therapy early.
The majority of patients who were prescribed adjuvant endocrine therapy for breast cancer at the Cross Cancer Institute remained on therapy for at least 2 years and were adherent. Longer follow-up by Cross Cancer Institute practitioners may help decrease discontinuation rates.
确定开始辅助内分泌治疗的乳腺癌患者中有多少人提前停药，并评估持续接受治疗患者的依从性。次要目标是探索可能的趋势，以查看某些因素是否与治疗的早期停药相关。
对病历和药房配药记录进行回顾性分析，纳入2006年1月1日至12月31日在十字癌症研究所开始接受乳腺癌辅助内分泌治疗的患者。
在346例患者中，81例（22%）在2年内停药。对265例接受治疗超过2年的患者计算的依从率显示，其中247例（93%）患者的依从性达到80%或更高。未接受化疗的患者以及在十字癌症研究所随访时间少于1年的患者更有可能提前停药。
在十字癌症研究所接受乳腺癌辅助内分泌治疗的大多数患者持续治疗至少2年且依从性良好。十字癌症研究所医生进行更长时间的随访可能有助于降低停药率。
